MENU
Remsima® is the world's first biosimilar monoclonal antibody developed by Celltrion. It was approved by international drug regulatory agencies across about 110 countries including the European Medicines Agency(EMA) and the U.S. Food and Drug Administration(FDA).
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.
Truxima® is the world's first oncology mAB biosimilar developed by Celltrion and approved by FDA and EMA.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.
Herzuma® is an oncology mAb biosimilar developed by Celltrion and approved by FDA and EMA.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.
Remsima®SC is the world's first SC formulation of biosimilar infliximab developed by Celltrion. It was approved by the European Medicines Agency(EMA), Korean Ministry of Food and Drug Safety(MFDS) and Health Canada.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.
The product descriptions on this website are for offering information only. They are not intended for promoting PR or sales campaigns.
For more details on pharmaceuticals, please consult a doctor or a medical specialist. This site is intended for all over the world.
「医療関係者の皆様へ」のページでは当社医療用医薬品を適正にご使用いただくため、国内の医療関係者の方を対象に情報を提供しています。一般の方に対する情報提供を目的としたものではないことをご了承ください。
あなたは医療関係者ですか?
The Celltrion Healthcare Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions.
If you are a resident of a country other than those to which the site is directed, please contact your local Celltrion Healthcare affiliate to obtain the appropriate product information for your country of residence.
The Celltrion Healthcare site that you have requested may be in a language that differs from your country of origin.
The Celltrion Healthcare site that you have requested may not be optimised for your screen size.
Do you wish to continue to this brand website?
Celltrion Healthcare provides this link as a courtesy and does not control the content
of the site you are about to enter into. Do you wish to continue?